For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
IBS or IBD? How to use C-reactive protein and faecal calprotectin tests
+Practice
In print
GASTROENTEROLOGY
IBS or IBD? How to use C-reactive protein and faecal calprotectin tests
Wednesday 29 September 2021, 12:15 AM

C-reactive protein and faecal calprotectin can be used to follow inflammatory bowel disease activity (Image: Transurfer on iStock)
Gastroenterologist Alan Fraser discusses the use of biomarkers for chronic inflammation when distinguishing between irritable bowel syndrome and inflammatory bowel disease
Key points, Increasing experience with faecal calprotectin is helping to define the place of this test in primary and secondary care when there is clinical suspic, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.